ERBB2 and breast cancer: The MAF1 promoter is significantly methylated in luminal (p < 1 x10-12), HER2-positive (p = 2.26 x 10−3), and TNBC (p = 5.26 x 10−12) subclasses of breast cancers, Fig 2B.